The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qualifies for additional ...

see the “Tecfidera and other interactions” section.) If you have questions about drug interactions that may affect you, ask your doctor or pharmacist. Here’s a table of drugs that can ...

Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.

"Similarly, the average markup on the drug dimethyl fumarate (generic Tecfidera) for patients with multiple sclerosis was more than 2,100 percent on commercial claims in 2022; the average ...

Tecfidera revenues are declining as multiple generic versions have been launched in North America, Brazil and certain European countries. Regulatory applications seeking approval for a biosimilar ...

Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera.